Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.
Cesar Augusto Perez, MD, medical oncologist, director, Drug Development, Florida Cancer Specialists and Research Institute, Sarah Cannon Research Institute, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.
KIN-2787 is an investigational, next-generation, pan-RAF inhibitor being evaluated for patients with solid tumors harboring class I, II, and III BRAF mutations, Perez explains. The agent was specifically developed to target class II and III mutations, which is an area of significant unmet need in patients with BRAF-mutated cancers.
KIN-2787 is being evaluated in an ongoing phase 1 trial (NCT04913285) for adult patients with BRAF-mutated solid tumors, including non–small cell lung cancer and melanoma, Perez says. This drug is unique because most available agents for patients with BRAF-mutated diseases were designed to target class I mutations. As such, the results of this study will be intriguing as KIN-2787 could have clinical utility across BRAF mutation–positive subgroups, Perez concludes.